Clofazimine

Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC50 = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer research[1][2][3][4][5].

Product Specifications

CAS Number

[2030-63-9]

UNSPSC

12171500

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; Interleukin Related

Type

Dye Reagents

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Clofazimine.html

Purity

99.79

Solubility

DMSO : 6.25 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

CC(/N=C1C(NC2=CC=C(Cl)C=C2)=CC3=NC4=C(C=CC=C4)N(C5=CC=C(Cl)C=C5)C3=C/1)C

Molecular Formula

C27H22Cl2N4

Molecular Weight

473.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Arbiser JL, et al. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995 Feb;32 (2 Pt 1) :241-7.|[2]Cholo MC, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012 Feb;67 (2) :290-8.|[3]Riccardi N, et al. Clofazimine: an old drug for never-ending diseases. Future Microbiol. 2020, 15:557-566.|[4]Ammerman NC, et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2017, 72 (2) :455-461. |[5]Durusu İZ, et al. Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. Leuk Res. 2017, 55:33-40. |[6]Ren YR, et al. Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes. PLoS One. 2008, 3 (12) :e4009.